CBD Reduced Involuntary Movements from Parkinson's Medication in Rats Without Reducing Its Benefits

CBD (30 mg/kg) and its fluorinated derivative PECS-101 (3 and 30 mg/kg) significantly reduced abnormal involuntary movements in L-DOPA-treated rats without reducing L-DOPA's motor benefits. CBD's antidyskinetic effects were blocked by CB1 and PPARy receptor antagonists and enhanced by TRPV-1 antagonism. CBD increased striatal anandamide and 2-AG concentrations and reduced neuroinflammation markers.

Unilateral 6-OHDA-lesioned rats were treated with L-DOPA for three weeks to induce dyskinesia, then received CBD or PECS-101 during the final two weeks. Abnormal involuntary movements were scored, and receptor antagonist studies identified mechanisms. Striatal endocannabinoid levels and inflammation markers were measured.

Dyskinesia affects up to 80% of Parkinson's patients on long-term L-DOPA therapy and is a major clinical problem. Finding a treatment that reduces dyskinesia without undermining L-DOPA's benefits would be a significant advance, and this preclinical evidence points to CBD as a candidate.

This study adds to growing evidence that cannabinoids may help manage movement disorders. The identification of multiple receptor pathways (CB1, PPARy, TRPV-1) involved in CBD's antidyskinetic effects could inform development of more targeted treatments for Parkinson's-related dyskinesia.

Animal model findings may not translate directly to humans. The 6-OHDA lesion model does not fully replicate the progressive nature of human Parkinson's disease. Only tested acute/subchronic CBD administration; long-term effects are unknown. Doses may not correspond to human-equivalent doses.